E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of pneumococcal disease |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of pneumococcal disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061353 |
E.1.2 | Term | Pneumococcal infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Objective 1: To evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs). Objective 2: To compare the antipneumococcal polysaccharide (PnPs) serotype-specific Immunoglobulin G (IgG) response rates (proportion of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL) at 30 days following Dose 3 for participants administered V114 versus participants administered Prevenar 13™. Objective 3: To compare anti-PnPs serotypespecific IgG Geometric Mean Concentrations (GMCs) for the 13 shared serotypes between V114 and Prevenar 13™ at 30 days following Dose 3 for participants administered V114 versus participants administered Prevenar 13™. |
|
E.2.2 | Secondary objectives of the trial |
Objective 1: To compare anti-PnPs serotypespecific IgG Geometric Mean Concentrations (GMCs) for the 2 unique V114 serotypes at 30 days following Dose 3 for participants administered V114 versus participants administered Prevenar 13™. Objective 2: To compare the anti-PnPs serotype-specific IgG response rates (proportion of participants meeting serotypespecific IgG threshold value of ≥0.35 μg/mL) at 30 days following Dose 4 for participants administered V114 versus participants administered Prevenar 13™ Objective 3: To compare anti-PnPs serotypespecific IgG GMCs at 30 days following Dose 4 for participants administered V114 versus participants administered Prevenar 13™. Objective 4: To evaluate the anti-PnPs serotype-specific opsonophagocytic activity (OPA) response rates and Geometric Mean Titers (GMTs) at 30 days following Dose 3 by each vaccination group.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Japanese male or female. |
|
E.4 | Principal exclusion criteria |
- Has a history of invasive pneumococcal disease (IPD) - Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid containing vaccine. - Has a known or suspected impairment of immunological function. - Has a history of congenital or acquired immunodeficiency. - Has or his/her mother has a documented human immunodeficiency virus (HIV) infection. - Has or his/her mother has a documented hepatitis B surface antigen-positive test. - Has known or history of functional or anatomic asplenia. - Has a history of autoimmune disease . - Has a known neurologic or cognitive behavioral disorder - Has received a dose of any pneumococcal vaccine prior to study entry. - Has received a blood transfusion or blood products, including immunoglobulins. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Percentage of Participants with Solicited Injection-Site Adverse Events 2. Percentage of Participants with Solicited Systemic AEs 3. Percentage of Participants with Vaccine-Related Serious Adverse Events 4. Percentage of Participants Meeting the Serotype Specific Immunoglobulin G Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 3 5. Geometric Mean Concentration of Serotype-Specific IgG for the 13 Shared Serotypes in V114 and PCV13 After Dose 3 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Day 1 to Day 14 post any vaccination 2. Day 1 to Day 14 post any vaccination 3. ~1 month after Dose 4 (Up to 23 months) 4. 30 Days after Dose 3 5. 30 Days after Dose 3 |
|
E.5.2 | Secondary end point(s) |
1. GMC of Serotype-Specific IgG for the 2 Unique V114 Serotypes After Dose 3 2. Percentage of Participants Meeting the Serotype Specific IgG Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 4 3. GMC of Serotype-Specific IgG for Each Serotype in V114 After Dose 4 4. Geometric Mean Titer of Serotype-Specific Opsonophagocytic Activity for Each Serotype in V114 After Dose 3 5. GMT of Serotype-Specific OPA for Each Serotype in V114 After Dose 4 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. 30 days after Dose 3 2. 30 Days after Dose 4 3. 30 Days after Dose 4 4. 30 Days after Dose 3 5. 30 Days after Dose 4
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The overall study ends when the last participant completes the last study-related contact, withdraws from the study, or is lost to follow-up. For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |